Larimar Therapeutics Reports Fourth Quarter and Full Year 2022 Operating and Financial Results
March 14, 2023 07:00 ET
|
Larimar Therapeutics
First cohort of Larimar’s Phase 2 dose exploration trial of CTI-1601 in participants with Friedreich’s ataxia (FA) is fully enrolled and proceeding as plannedLarimar expects to provide an update on...
Larimar Therapeutics Appoints Dr. Gopi Shankar as Chief Development Officer
February 07, 2023 16:05 ET
|
Larimar Therapeutics
Biologics expert and long-time veteran of Johnson & Johnson will be responsible for the strategic development of Larimar’s clinical and R&D programs BALA CYNWYD, Pa., Feb. 07, 2023 (GLOBE...
Larimar Therapeutics to Present at the 34th Annual Piper Sandler Healthcare Conference
November 21, 2022 16:05 ET
|
Larimar Therapeutics
BALA CYNWYD, Pa., Nov. 21, 2022 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare...
Larimar Therapeutics Reports Third Quarter 2022 Operating and Financial Results
November 10, 2022 07:00 ET
|
Larimar Therapeutics
First cohort of Larimar’s Phase 2 dose exploration trial of CTI-1601 in Friedreich’s ataxia patients is ongoing and proceeding in line with the Company’s planned timelineLarimar expects to provide an...
Larimar Therapeutics to Participate in the Guggenheim 4th Annual Immunology & Neurology Day
November 07, 2022 16:05 ET
|
Larimar Therapeutics
BALA CYNWYD, Pa., Nov. 07, 2022 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare...
Larimar Therapeutics Announces Issuance of U.S. Patent Providing Composition of Matter Protection for CTI-1601
October 20, 2022 08:00 ET
|
Larimar Therapeutics
Patent extends Larimar’s intellectual property protection for CTI-1601 into at least July 2040 BALA CYNWYD, Pa., Oct. 20, 2022 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq:...
Larimar Therapeutics Announces Oral and Poster Presentations at the Upcoming International Congress for Ataxia Research
October 19, 2022 16:05 ET
|
Larimar Therapeutics
BALA CYNWYD, Pa., Oct. 19, 2022 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare...
Larimar Therapeutics Announces Closing of Underwritten Offering and Full Exercise of Option to Purchase Additional Shares
September 16, 2022 13:00 ET
|
Larimar Therapeutics
BALA CYNWYD, Pa., Sept. 16, 2022 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (“Larimar” or the “Company”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments...
Larimar Therapeutics Announces $70 Million Underwritten Offering
September 14, 2022 07:04 ET
|
Larimar Therapeutics
BALA CYNWYD, Pa., Sept. 14, 2022 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (“Larimar” or the “Company”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments...
Larimar Therapeutics Announces FDA Clearance to Initiate the 25 mg Cohort of a Phase 2 Dose Exploration Trial of CTI-1601 in Friedreich’s Ataxia Patients
September 14, 2022 07:01 ET
|
Larimar Therapeutics
Initiation of the Phase 2 trial is expected in Q4 2022, with top-line data expected in 2H 2023 Company management hosting webcast and conference call today at 8:30 a.m. ET BALA...